Avalo Therapeutics Maintains Buy Rating with $36 Price Target

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Avalo Therapeutics with a $36.00 price target. Thompson CFA has a 51.91% success rate on recommended stocks and an average return of 1.6%. Avalo Therapeutics reported a GAAP net loss of $13.15 million for Q1, compared to a loss of $121.29 million in the same period last year. The analyst consensus is Strong Buy with a price target consensus of $30.33.

Avalo Therapeutics, Inc. (NASDAQ: AVTX) reported a GAAP net loss of $13.15 million for Q1 2025, compared to a loss of $121.29 million in the same period last year. Despite the significant loss, analysts maintain a bullish stance on the company, with a consensus rating of "Strong Buy" and an average price target of $30.33 [1].

Stifel Nicolaus analyst Alex Thompson CFA maintained a "Buy" rating on Avalo Therapeutics with a $36.00 price target. Thompson CFA has a 51.91% success rate on recommended stocks and an average return of 1.6% [2]. The analyst's optimism is shared by other market analysts, with six brokerages currently covering the stock and providing a "Buy" recommendation [3].

Institutional investors hold 87.06% of Avalo Therapeutics' stock, indicating significant interest in the company. Northern Trust Corp, Marshall Wace LLP, Tower Research Capital LLC, Geode Capital Management LLC, and Affinity Asset Advisors LLC have recently increased their stakes in the company [4]. The company's stock has been trading at $6.58, with a 50-day moving average of $4.84 and a 200-day moving average of $5.91 [5].

Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapies for immune dysregulation disorders. Its drug candidates, AVTX-009 and AVTX-008, are in Phase I and Phase I/II trials, respectively [6]. The company's earnings loss of ($1.25) per share in Q1 2025 was below the consensus estimate of ($1.07), indicating that the company may be underestimating its losses [7].

Despite the recent earnings loss, analysts believe that Avalo Therapeutics has the potential to deliver strong returns in the long term. The company's focus on innovative therapies for immune dysregulation disorders positions it well to capture a share of the growing biotechnology market.

References:
[1] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/
[2] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/
[3] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/
[4] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/
[5] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/
[6] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/
[7] https://www.marketbeat.com/instant-alerts/avalo-therapeutics-inc-nasdaqavtx-given-consensus-recommendation-of-buy-by-brokerages-2025-07-28/